文献速递脊柱关节炎

阿达木单抗治疗外周型脊柱关节炎:改良MDA应答的表现与预测因素

Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-12-29

本研究基于ABILITY-2研究,评估四种改良最小疾病活动度(MDA)标准在外周型脊柱关节炎中的同时效度与区分度,并确定改良MDA应答的预测因素。结果显示四种改良MDA版本与PSpARC缓解强相关,能区分阿达木单抗与安慰剂,早期改良MDA应答是长期MDA达成的稳健预测因素。

要点

  • 四种改良MDA版本与PSpARC缓解强相关(rtet>0.95),与ASDAS ID相关性稍弱(rtet>0.75)。
  • 阿达木单抗组达成改良MDA的患者显著多于安慰剂组(P<0.001)。
  • 12周阿达木单抗治疗后的改良MDA应答可稳健预测3年长期MDA达成(OR 11.38-37.85)。

核心结论

  • 四种改良MDA版本均显示同时效度,能良好区分阿达木单抗与安慰剂治疗组。
  • 早期改良MDA应答比基线特征更一致地预测长期改良MDA达成。
  • 六种版本中的五种改良MDA可作为外周型SpA患者的合适治疗目标。

研究设计与样本

  • 基于ABILITY-2研究,衍生四种改良MDA版本,分别使用SPARCC附着点炎指数或LEI并排除银屑病。
  • 评估同时效度(与PSpARC缓解、ASDAS ID、医生整体评估的相关性)和12周治疗区分度。
  • 采用多元逻辑回归确定长期改良MDA应答和持续改良MDA的基线预测因素。

主要发现

  • 四种改良MDA版本在第12周及第1-3年与PSpARC缓解呈更强正相关(rtet>0.95),与ASDAS ID相关性为rtet>0.75。
  • 第12周显示区分度(P<0.001),阿达木单抗组达成所有四种改良MDA版本的患者显著多于安慰剂组。
  • 使用LEI或SPARCC附着点炎指数,约40-60%阿达木单抗治疗患者在第1-3年达成改良MDA。
  • 12周阿达木单抗治疗后达成改良MDA应答是3年内长期改良MDA达成的稳健阳性预测因素(LEI版OR 11.38-27.13;SPARCC版OR 17.98-37.85)。

关键数值与推荐

  • 改良MDA版本与PSpARC缓解相关性rtet>0.95,与ASDAS ID相关性rtet>0.75(第12周及第1-3年)。
  • 12周治疗区分度P<0.001。
  • 阿达木单抗组第1-3年改良MDA达成率约40-60%(LEI或SPARCC附着点炎指数)。
  • 12周改良MDA应答预测长期MDA的OR:LEI版11.38-27.13,SPARCC版17.98-37.85。

临床怎么用

  • 在外周型SpA中,可采用改良MDA(使用LEI或SPARCC附着点炎指数并排除银屑病)作为治疗目标。
  • 早期(12周)达成改良MDA可预测长期治疗成功,应作为临床监测重点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the concurrent validity and discrimination of criteria for modified minimal disease activity (MDA) in peripheral spondyloarthritis (SpA) following filter principles of Outcome Measures in Rheumatology (OMERACT) and to determine predictors of modified MDA response. METHODS: Four modified MDA versions were derived in the ABILITY-2 study using the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index or the Leeds Enthesitis Index (LEI) while excluding psoriasis. To assess concurrent validity, modified MDA versions were correlated with Peripheral Spondyloarthritis Response Criteria (PSpARC) remission, Ankylosing Spondylitis Disease Activity Score showing inactive disease (ASDAS ID), and physician global assessment of disease activity. Treatment discrimination was assessed between adalimumab and placebo at week 12. Multiple logistic regression was used to determine baseline predictors of long-term modified MDA responses and sustained modified MDA. RESULTS: The 4 modified MDA versions showed a stronger positive correlation with PSpARC remission (rtet > 0.95) versus ASDAS ID (rtet > 0.75) at week 12 and years 1-3 and were able to show discrimination (P < 0.001). Responsiveness was shown at week 12; significantly more patients receiving adalimumab versus placebo achieved all 4 versions of modified MDA. Approximately 40-60% of patients treated with adalimumab achieved modified MDA using the LEI or SPARCC enthesitis index at years 1-3. Achieving modified MDA response after 12 weeks of adalimumab treatment was a robust positive predictor of attaining long-term modified MDA through 3 years (odds ratio [OR] 11.38-27.13 for modified MDA using the LEI; OR 17.98-37.85 for modified MDA using the SPARCC enthesitis index). CONCLUSION: All 4 versions of modified MDA showed concurrent validity and discriminated well between adalimumab and placebo treatment groups. Early modified MDA response is a more consistent predictor of long-term modified MDA achievement than baseline characteristics. The 5 of 6 versions of modified MDA could be an appropriate treatment target in patients with peripheral SpA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Coates LC, Abraham S, Tillett W, et al. Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab. Arthritis Care Res (Hoboken). 2021. PMID: 32937016. doi:10.1002/acr.24442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。